Obsidian Therapeutics will present updated Phase 1/2 data on amsoki-cel (OBX-115) in advanced melanoma at the SITC 2026 Annual Meeting, according to an announcement distributed through BioSpace.

The presentation covers the company's engineered cell therapy candidate, amsoki-cel, also known by its research code OBX-115. The data update applies to patients with advanced melanoma, the stage of the disease in which tumors have spread or become unresectable and where treatment options remain limited after frontline immunotherapy.

The upcoming readout belongs to an ongoing Phase 1/2 trial. Phase 1/2 designs typically dose escalating cohorts to establish safety and tolerability before expanding to assess clinical activity — the standard development pathway for investigational cell therapies in solid tumors.

Why SITC matters for this program

The Society for Immunotherapy of Cancer (SITC) Annual Meeting serves as one of the principal scientific venues for late-breaking immuno-oncology data. A company selecting SITC for an updated dataset signals that the findings carry tumor immunotherapy relevance for an audience of investigators and clinicians.

Amsoki-cel is Obsidian Therapeutics' lead oncology asset. The company has positioned the candidate within the cell-therapy field, an area that has produced durable responses in hematologic malignancies but has struggled to replicate that success in solid tumors such as melanoma.

What the announcement does and does not say

The announcement, as carried by BioSpace, confirms the presentation event and the trial stage but does not disclose the updated efficacy figures, response rates, or safety profile ahead of the meeting. Those specifics — objective response rate, duration of response, and treatment-related adverse events — will accompany the presentation itself at SITC 2026.

For dermatologists and oncology teams managing advanced melanoma, the details that matter at readout will include:

• Objective response rate in the treated cohort
• Durability of any responses
• Safety and tolerability signals across dose levels
• How the candidate compares with approved adoptive cell therapies

Context for melanoma treatment

Advanced melanoma treatment has expanded over the past decade with checkpoint inhibitors and targeted therapies, yet a substantial fraction of patients still progress on current standards of care. Investigational cell therapies such as amsoki-cel aim to address that unmet need.

The forthcoming SITC 2026 presentation will determine whether the updated Phase 1/2 data strengthen the case for advancing OBX-115 into later-stage melanoma development.